Source link : https://foot.biz/2024/06/19/fda-clears-gsks-rsv-vaccine-for-adults-ages-50-59/
The U.S. Food and Drug Administration on Friday approved GSK’s respiratory syncytial virus vaccine for high-risk adults ages 50 to 59, expanding the shot’s accessibility to younger patients…
Source : United Press International
—-
Author : foot.biz
Publish date : 2024-06-19 08:06:39
Copyright for syndicated content belongs to the linked Source.